Dr Anna Olsson-Brown

Dr Anna Olsson-Brown is a Consultant in Medical Oncology. She specialises in the systemic
treatment of skin cancers; sarcoma; immunotherapeutic toxicities, and early phase/translational
clinical trials.

She is the Clinical Director for the Acute Division at the Clatterbridge Cancer Centre, Liverpool
and an Honorary Senior Lecturer at the University of Liverpool. She has a background in clinical
pharmacology and specialises in the management of immunotherapeutic toxicities, melanoma,
sarcoma and early phase/ translational clinical trials.

She is the current immunotherapy toxicity work stream lead for the NIHR Oncology Translational
Research Committee (O-TRC) and a board member of UKASC. She is a founding member and
current CEO of the National Immunotherapy Clinical Network (IOCN) and sits on the UK
Chemotherapy Board within this role. Within Clatterbridge she is the Chair of the Immunotherapy
Committee and Deputy Chair of Supportive Care SRG. She is a current Clinical Advisor to Health
Education England and the British Medical Journal, Oncology representative of the Symposium
Committee at the Royal College of Physicians of Edinburgh, representative on the Association
of Cancer Physicians and RCPE new consultant committees and senior advisor to the National
Oncology Collaboration for Trainee Research (NOTCH).